Britain and America have secured a significant trade agreement that will maintain zero import taxes on UK pharmaceutical shipments going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This commitment ensures that duties on these key exports will stay at nothing for a duration of three years.
This deal follows earlier statements to hike tariffs on patented pharmaceutical products, with figures mentioned as high as double the cost.
"This arrangement with the United Kingdom reinforces the worldwide climate for new treatments and brings much-needed balance to transatlantic medicine commerce," a release said.
Economic Impact
Drugs constitute one of the Britain's most significant export categories to the US, which is easily the biggest market for large British pharmaceutical firms.
Export figures reveal that in the 12 months leading up to last September, the UK shipped medicines valued at £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that period.
"This agreement safeguards jobs, increases funding and facilitates the UK to emerge as a international leader for life sciences," a government official remarked.
Detailed UK Commitments
The deal includes several key commitments from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a target to increase overall public funding on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates were more than 20%.
Recent Tensions
The deal takes place against a long-running tension between the sector and the British authorities over medicine costs and approval rates.
This friction were exacerbated by claims that American consumers were paying a premium for the same drugs than people in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward American operations.
One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a share of its resources over the previous ten-year period.
